{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:14:00Z","timestamp":1792512840513,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00467-021-05069-w","type":"journal-article","created":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T09:03:22Z","timestamp":1623834202000},"page":"357-365","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1487-6671","authenticated-orcid":false,"given":"Quentin","family":"Bertrand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Mignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Couderc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Maisin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Cambier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Baudouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Peyneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Desch\u00eanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Dossier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,16]]},"reference":[{"key":"5069_CR1","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00467-018-4149-2","volume":"34","author":"C Dossier","year":"2019","unstructured":"Dossier C, Delbet JD, Boyer O, Daoud P, Mesples B, Pellegrino B, See H, Benoist G, Chace A, Larakeb A, Hogan J, Desch\u00eanes G (2019) Five-year outcome of children with idiopathic nephrotic syndrome: the NEPHROVIR population-based cohort study. Pediatr Nephrol 34:671\u2013678. https:\/\/doi.org\/10.1007\/s00467-018-4149-2","journal-title":"Pediatr Nephrol"},{"key":"5069_CR2","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1054\/bjoc.2001.2127","volume":"85","author":"PW Johnson","year":"2001","unstructured":"Johnson PW, Glennie MJ (2001) Rituximab: mechanisms and applications. Br J Cancer 85:1619\u20131623. https:\/\/doi.org\/10.1054\/bjoc.2001.2127","journal-title":"Br J Cancer"},{"key":"5069_CR3","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s00467-004-1434-z","volume":"19","author":"K Benz","year":"2004","unstructured":"Benz K, D\u00f6tsch J, Rascher W, Stachel D (2004) Change of the course of steroid dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 19:794\u2013797. https:\/\/doi.org\/10.1007\/s00467-004-1434-z","journal-title":"Pediatr Nephrol"},{"key":"5069_CR4","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1681\/ASN.2014080799","volume":"26","author":"P Ravani","year":"2015","unstructured":"Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, Pasini A, Montini G, Edefonti A, Belingheri M, De Giovanni D, Barbano G, Degl'Innocenti L, Scolari F, Murer L, Reiser J, Fornoni A, Ghiggeri GM (2015) Rituximab in children with steroid-dependant nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol 26:2259\u20132266. https:\/\/doi.org\/10.1681\/ASN.2014080799","journal-title":"J Am Soc Nephrol"},{"key":"5069_CR5","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito HH, Ishikura K, Ito S, Ohashi Y, Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group (2014) Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384:1273\u20131281. https:\/\/doi.org\/10.1016\/S0140-6736(14)60541-9","journal-title":"Lancet"},{"key":"5069_CR6","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","volume":"172","author":"B Basu","year":"2018","unstructured":"Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra TKS, Schaefer F (2018) Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial. JAMA Pediatr 172:757\u2013764. https:\/\/doi.org\/10.1001\/jamapediatrics.2018.1323","journal-title":"JAMA Pediatr"},{"key":"5069_CR7","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1136\/ard.2007.083162","volume":"67","author":"D Albert","year":"2008","unstructured":"Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, Pullman-Mooar S, Barnack F, Striebich C, Looney RJ, Prak ET, Kimberly R, Zhang Y, Eisenberg R (2008) Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 67:1724\u20131731. https:\/\/doi.org\/10.1136\/ard.2007.083162","journal-title":"Ann Rheum Dis"},{"key":"5069_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jneuroim.2017.12.021","volume":"316","author":"T Li","year":"2018","unstructured":"Li T, Zhang LJ, Zhang QX, Yang CS, Zhang C, Li YJ, Shi FD, Yang L (2018) Anti-rituximab antibody in patients with NMOSDs treated with low dose rituximab. J Neuroimmunol 316:107\u2013111. https:\/\/doi.org\/10.1016\/j.jneuroim.2017.12.021","journal-title":"J Neuroimmunol"},{"key":"5069_CR9","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1007\/s10067-017-3848-6","volume":"36","author":"JT Einarsson","year":"2017","unstructured":"Einarsson JT, Evert M, Geborek P, Saxne T, Lundgren M, Kapetanovic MC (2017) Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies. Clin Rheumatol 36:2743\u20132750. https:\/\/doi.org\/10.1007\/s10067-017-3848-6","journal-title":"Clin Rheumatol"},{"key":"5069_CR10","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1136\/annrheumdis-2019-215200","volume":"78","author":"C Wincup","year":"2019","unstructured":"Wincup C, Menon M, Smith E, Schwartz A, Isenberg D, Jury EC, Mauri C, ABIRISK Consortium (2019) Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus. Ann Rheum Dis 78:1140\u20131142. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215200","journal-title":"Ann Rheum Dis"},{"key":"5069_CR11","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s00467-014-2794-7","volume":"29","author":"YH Ahn","year":"2014","unstructured":"Ahn YH, Kang HG, Lee JM, Choi HJ, Ha IS, Cheong HI (2014) Development of antirituximab antibodies in children with nephrotic syndrome. Pediatr Nephrol 29:1461\u20131464. https:\/\/doi.org\/10.1007\/s00467-014-2794-7","journal-title":"Pediatr Nephrol"},{"key":"5069_CR12","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/bjh.15177","volume":"184","author":"C Vendramin","year":"2019","unstructured":"Vendramin C, Thomas M, Westwood JP, McGuckin S, Scully M (2019) Rituximab-induced acute and delayed serum sickness in thrombotic thrombocytopenic purpura: the role of anti-rituximab antibodies. Br J Haematol 184:858\u2013861. https:\/\/doi.org\/10.1111\/bjh.15177","journal-title":"Br J Haematol"},{"key":"5069_CR13","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-L\u00f3pez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R (1997) IDEC-C2B8 (Rituximab) anti CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Blood Sep 90:2188\u20132195","journal-title":"Blood Sep"},{"key":"5069_CR14","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/art.20430","volume":"50","author":"RJ Looney","year":"2004","unstructured":"Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab. Arthritis Rheum 50:2580\u20132589. https:\/\/doi.org\/10.1002\/art.20430","journal-title":"Arthritis Rheum"},{"key":"5069_CR15","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1002\/art.21260","volume":"52","author":"J Pijpe","year":"2005","unstructured":"Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, Vissink A, Kallenberg CG, Bootsma H (2005) Rituximab treatment in patients with primary Sj\u00f6gren's syndrome: an open-label phase II study. Arthritis Rheum 52:2740\u20132750. https:\/\/doi.org\/10.1002\/art.21260","journal-title":"Arthritis Rheum"},{"key":"5069_CR16","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1002\/art.22046","volume":"54","author":"KG Smith","year":"2006","unstructured":"Smith KG, Jones RB, Burns SM, Jayne DR (2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 54:2970\u20132982. https:\/\/doi.org\/10.1002\/art.22046","journal-title":"Arthritis Rheum"},{"key":"5069_CR17","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1002\/art.23059","volume":"56","author":"E Keystone","year":"2007","unstructured":"Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, Udell J, Cravets MW, Agarwal S, Cooper S, Magrini F (2007) Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis. Arthritis Rheum 56:3896\u20133908. https:\/\/doi.org\/10.1002\/art.23059","journal-title":"Arthritis Rheum"},{"key":"5069_CR18","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s00467-020-04629-w","volume":"35","author":"S Fujinaga","year":"2020","unstructured":"Fujinaga S, Nishino T, Endo S, Umeda C, Watanabe Y, Nakagawa M (2020) Unfavorable impact of anti-rituximab antibodies on clinical outcomes in children with complicated steroid-dependent nephrotic syndrome. Pediatr Nephrol 35:2003\u20132008. https:\/\/doi.org\/10.1007\/s00467-020-04629-w","journal-title":"Pediatr Nephrol"},{"key":"5069_CR19","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s00467-018-3960-0","volume":"33","author":"S Fujinaga","year":"2018","unstructured":"Fujinaga S, Nishino T (2018) Is cytokine-release syndrome the cause of rituximab treatment-related infusion reactions in children with nephrotic syndrome? Impact of anti-rituximab antibodies. Pediatr Nephrol 33:1097\u20131098. https:\/\/doi.org\/10.1007\/s00467-018-3960-0","journal-title":"Pediatr Nephrol"},{"key":"5069_CR20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.kint.2019.09.033","volume":"97","author":"EY Chan","year":"2020","unstructured":"Chan EY, Webb H, Yu E, Ghiggeri GM, Kemper MJ, Ma AL, Yamamura T, Sinha A, Bagga A, Hogan J, Dossier C, Vivarelli M, Liu ID, Kamei K, Ishikura K, Saini P, Tullus K (2020) Both the rituximab dose and maintenance immunosuppression in steroid-dependent\/frequently-relapsing nephrotic syndrome have important effects on outcomes. Kidney Int 97:393\u2013401. https:\/\/doi.org\/10.1016\/j.kint.2019.09.033","journal-title":"Kidney Int"},{"key":"5069_CR21","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1007\/s00467-017-3718-0","volume":"32","author":"K Kamei","year":"2017","unstructured":"Kamei K, Ishikura K, Sako M, Aya K, Tanaka R, Nozu K, Kaito H, Nakanishi K, Ohtomo Y, Miura K, Takahashi S, Morimoto T, Kubota W, Ito S, Nakamura H, Iijima K, Rituximab for Childhood-Onset Refractory Nephrotic Syndrome (RCRNS) Study Group (2017) Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab. Pediatr Nephrol 32:2071\u20132078. https:\/\/doi.org\/10.1007\/s00467-017-3718-0","journal-title":"Pediatr Nephrol"},{"key":"5069_CR22","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1093\/ndt\/gfz041","volume":"34","author":"S Boyer-Suavet","year":"2019","unstructured":"Boyer-Suavet S, Andreani M, Cremoni M, Brglez V, Benzaken S, Bernard G, Nachman P, Esnault V, Seitz-Polski B (2019) Rituximab bioavailability in primary membranous nephropathy. Nephrol Dial Transplant 34:1423\u20131425. https:\/\/doi.org\/10.1093\/ndt\/gfz041","journal-title":"Nephrol Dial Transplant"},{"key":"5069_CR23","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1182\/blood.v99.3.754","volume":"99","author":"G Cartron","year":"2002","unstructured":"Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754\u2013758. https:\/\/doi.org\/10.1182\/blood.v99.3.754","journal-title":"Blood"},{"key":"5069_CR24","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00467-009-1191-0","volume":"24","author":"K Kamei","year":"2009","unstructured":"Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, Saito M, Yoneko M, Iijima K (2009) Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 24:1321\u20131328. https:\/\/doi.org\/10.1007\/s00467-009-1191-0","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"5069_CR25","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00467-017-3866-2","volume":"33","author":"S Fujinaga","year":"2018","unstructured":"Fujinaga S, Sakuraya K (2018) Single infusion of low-dose ofatumumab in a child with complicated nephrotic syndrome with anti-rituximab antibodies. Pediatr Nephrol Mar 33(3):527\u2013528. https:\/\/doi.org\/10.1007\/s00467-017-3866-2","journal-title":"Pediatr Nephrol Mar"},{"key":"5069_CR26","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s00467-017-3621-8","volume":"32","author":"CS Wang","year":"2017","unstructured":"Wang CS, Liverman RS, Garro R, George RP, Glumova A, Karp A, Jernigan S, Warshaw B (2017) Ofatumumab for the treatment of childhood nephrotic syndrome. Pediatr Nephrol 32:835\u2013841. https:\/\/doi.org\/10.1007\/s00467-017-3621-8","journal-title":"Pediatr Nephrol"},{"key":"5069_CR27","doi-asserted-by":"publisher","unstructured":"Dossier C, Prim B, Moreau C, Kwon T, Maisin A, Nathanson S, De Gennes C, Barsotti K, Bourrassi A, Hogan J, Desch\u00eanes G (2020) A global antiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome. Pediatr Nephrol. https:\/\/doi.org\/10.1007\/s00467-020-04811-0","DOI":"10.1007\/s00467-020-04811-0"},{"key":"5069_CR28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.nephro.2017.08.040","volume":"5","author":"S Boyer","year":"2017","unstructured":"Boyer S, Benzaken S, Bernard G, Esnault V, Seitz-Polski B (2017) R\u00e9activit\u00e9 crois\u00e9e des anticorps anti-rituximab neutralisants avec les anti-CD20 de troisi\u00e8me g\u00e9n\u00e9ration : une alternative th\u00e9rapeutique dans la glom\u00e9rulopathie extramembraneuse? Oral communication. Nephrol Ther 5:267. https:\/\/doi.org\/10.1016\/j.nephro.2017.08.040","journal-title":"Nephrol Ther"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-021-05069-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-021-05069-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-021-05069-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T06:33:56Z","timestamp":1643956436000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-021-05069-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,16]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["5069"],"URL":"https:\/\/doi.org\/10.1007\/s00467-021-05069-w","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,16]]},"assertion":[{"value":"11 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}